Edward Patz
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) (NCT04314089) | Edward Patz | 2020-06-09 |
Track Edward Patz automatically
Every clearance here is in the API, with alerts when new ones post.